2,2'-azobis(2-amidinopropane) has been researched along with Chronic Kidney Failure in 1 studies
2,2'-azobis(2-amidinopropane): water-soluble free-radical initiator
| Excerpt | Relevance | Reference |
|---|---|---|
| " The results thus suggest that a daily dosage of 2." | 2.68 | n-3 fatty acids do not enhance LDL susceptibility to oxidation in hypertriacylglycerolemic hemodialyzed subjects. ( Biasia, F; Biffanti, S; Bonanome, A; De Luca, M; Munaretto, G; Pagnan, A; Pradella, M, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bonanome, A | 1 |
| Biasia, F | 1 |
| De Luca, M | 1 |
| Munaretto, G | 1 |
| Biffanti, S | 1 |
| Pradella, M | 1 |
| Pagnan, A | 1 |
1 trial available for 2,2'-azobis(2-amidinopropane) and Chronic Kidney Failure
| Article | Year |
|---|---|
n-3 fatty acids do not enhance LDL susceptibility to oxidation in hypertriacylglycerolemic hemodialyzed subjects.
Topics: Amidines; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Fatty Acids, Omega-3; Female; Humans; Hyp | 1996 |